Susheel Kodali

Nov 5, 2024 | healio.com | Erik Swain |Richard Smith |Susheel Kodali |Suzanne V. Arnold

You've successfully added Intervention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Transcatheter tricuspid valve replacement plus medical therapy improved outcomes vs. medical therapy alone in patients with severe tricuspid regurgitation.

Feb 2, 2024 | healio.com | Erik Swain |Susheel Kodali

• The FDA approved the first transcatheter tricuspid valve replacement system. • The system is indicated for patients with severe symptomatic tricuspid regurgitation despite optimal medical therapy. The FDA approved the first transcatheter tricuspid valve replacement system for the treatment of symptomatic severe tricuspid regurgitation despite optimal medical therapy.

Oct 26, 2023 | healio.com | Erik Swain |Katie Kalvaitis |Yousif Ahmad |Susheel Kodali

You've successfully added Cardiac Vascular Intervention: Structural to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Transcatheter tricuspid valve replacement was feasible in most of a cohort of patients with severe tricuspid regurgitation.

Oct 25, 2023 | hmpgloballearningnetwork.com | Susheel Kodali

As TAVR's procedural reach continues to expand into younger populations, there has been a rise in focus around lifetime management of aortic stenosis. Bioprosthetic heart valves, whether TAVR or surgical AVR, do not last a lifetime, and "there are likely to be multiple interventions," said Dr. Susheel Kodali, noting "there's a clear need" for a transcatheter solution.